Statements of Changes in Stockholders’ Equity - USD ($) $ in Thousands	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Common stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance at beginning of the period at Dec. 31, 2013	$ 23,348			$ 5,348		$ (44,727)	$ (39,379)
Balance at beginning of the period (in shares) at Dec. 31, 2013	27,248,746		237,026
Increase (Decrease) in Stockholders' Equity
Exercise of preferred stock warrant	$ 6,436	$ 993
Exercise of preferred stock warrant (in shares)	5,101,816	787,402
Issuance of preferred stock upon conversion of convertible debt	$ 13,184
Issuance of preferred stock upon conversion of convertible debt (in shares)	13,184,383
Issuance of preferred/Common stock		$ 30,478
Issuance of preferred stock/Common stock ( in shares)		24,409,444
Issuance of convertible notes				2,071			2,071
Extinguishment of convertible notes		$ 5,013
Debt Conversion, Converted Instrument, Shares Issued		3,947,363
Extinguishment of convertible notes				(1,150)			(1,150)
Exchange of preferred stock for common stock in connection with the Merger	$ (42,968)	$ (36,484)	$ 10	79,442			79,452
Exchange of preferred stock for common stock in connection with the Merger ( in shares)	(45,534,945)	(29,144,209)	9,901,700
Issuance of common stock in connection with the Merger			$ 3	31,321			31,324
Issuance of common stock in connection with the Merger ( in shares)			2,610,871
Exchange of warrants in connection with the Merger				167			167
Exercise of stock options				90			90
Exercise of stock options (in shares)			98,405
Issuance of warrants in connection with Hercules notes				248			248
Issuance of common stock upon vesting of restricted stock units				(297)			(297)
Issuance of common stock upon vesting of restricted stock units ( in shares)			27,540
Stock-based compensation expense and vesting of restricted stock				1,719			1,719
Stock-based compensation expense and vesting of restricted stock ( in shares)			45,301
Net loss						(41,844)	(41,844)
Balance at end of the period at Dec. 31, 2014			$ 13	118,959		(86,571)	32,401
Balance at end of the period (in shares) at Dec. 31, 2014			12,920,843
Increase (Decrease) in Stockholders' Equity
Issuance of preferred/Common stock			$ 11	47,951			47,962
Issuance of preferred stock/Common stock ( in shares)			10,558,208
Stock issued in connection with purchase of Bioceros				4,568			4,568
Stock issued in connection with purchase of Bioceros ( in shares)			788,960
Exercise of stock options				355			355
Exercise of stock options (in shares)			130,920
Retirement of common stock				(177)			(177)
Retirement of common stock (in shares)			(34,617)
Stock-based compensation expense and vesting of restricted stock				3,470			3,470
Stock-based compensation expense and vesting of restricted stock ( in shares)			13,259
Foreign currency translation adjustment					$ (23)		(23)
Net loss						(52,188)	(52,188)
Balance at end of the period at Dec. 31, 2015			$ 24	$ 175,126	$ (23)	$ (138,759)	$ 36,368
Balance at end of the period (in shares) at Dec. 31, 2015			24,377,573